About Ligand Pharmaceuticals
Ligand Pharmaceuticals is a company based in San Diego (United States) founded in 1987.. The company has 68 employees as of December 31, 2024. Ligand Pharmaceuticals has completed 15 acquisitions, including Ab Initio, Apeiron Biologics and Crystal Biosciences. Ligand Pharmaceuticals offers products and services including Captisol Technology and Royalty Portfolio Management.
- Headquarter San Diego, United States
- Employees 68 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ligand Pharmaceuticals Incorporated
-
Annual Revenue
$167.13 M27.28as on Dec 31, 2024
-
Net Profit
$-4.03 M-107.73as on Dec 31, 2024
-
EBITDA
$60.41 M27.89as on Dec 31, 2024
-
Latest Funding Round
$650 M (USD), Post-IPO
May 18, 2018
-
Investors
-
Employee Count
68
as on Dec 31, 2024
-
Investments & Acquisitions
Ab Initio
& 14 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Ligand Pharmaceuticals
Ligand Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol LGND in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Ligand Pharmaceuticals
Ligand Pharmaceuticals offers a comprehensive portfolio of products and services, including Captisol Technology and Royalty Portfolio Management. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
This technology is utilized for enhancing drug solubility and stability in development processes
Royalties from biopharmaceutical programs are managed across various disease areas
Unlock access to complete
Unlock access to complete
Funding Insights of Ligand Pharmaceuticals
- Total Funding Total Funding
- Total Rounds 2
- Last Round Post-IPO — $650.0M
-
First Round
First Round
(13 Aug 2014)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2018 | Amount | Post-IPO - Ligand Pharmaceuticals | Valuation |
investors |
|
| Aug, 2014 | Amount | Post-IPO - Ligand Pharmaceuticals | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Ligand Pharmaceuticals
Ligand Pharmaceuticals has strategically engaged in corporate development activities, having acquired 15 companies. Notable acquisitions include Ab Initio, Apeiron Biologics and Crystal Biosciences. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Novel cow antibodies are developed for therapeutic applications.
|
2018 | ||||
|
Developer of immuno-oncology antibody therapeutics
|
2016 | ||||
|
GPCR-modulating protein agents and immuno-oncology drugs are developed.
|
2015 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Ligand Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ligand Pharmaceuticals Comparisons
Competitors of Ligand Pharmaceuticals
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ligand Pharmaceuticals
Frequently Asked Questions about Ligand Pharmaceuticals
When was Ligand Pharmaceuticals founded?
Ligand Pharmaceuticals was founded in 1987 and raised its 1st funding round 27 years after it was founded.
Where is Ligand Pharmaceuticals located?
Ligand Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Ligand Pharmaceuticals?
Todd Davis is the current CEO of Ligand Pharmaceuticals.
How many employees does Ligand Pharmaceuticals have?
As of Dec 31, 2024, the latest employee count at Ligand Pharmaceuticals is 68.
What is the annual revenue of Ligand Pharmaceuticals?
Annual revenue of Ligand Pharmaceuticals is $167.13M as on Dec 31, 2024.
What does Ligand Pharmaceuticals do?
Ligand Pharmaceuticals was founded in 1987 and is headquartered in San Diego, United States. Operations are centered on the biopharmaceutical sector, where drugs are developed, manufactured, and commercialized for therapeutic applications. The company is led by CEO Todd Davis. Focus is placed on innovative pharmaceutical solutions, with activities conducted primarily in the domestic market. Domain services support ongoing research and production efforts.
What products or services does Ligand Pharmaceuticals offer?
Ligand Pharmaceuticals offers Captisol Technology and Royalty Portfolio Management.
Is Ligand Pharmaceuticals publicly traded?
Yes, Ligand Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol LGND.
How many acquisitions has Ligand Pharmaceuticals made?
Ligand Pharmaceuticals has made 15 acquisitions, including Ab Initio, Apeiron Biologics, and Crystal Biosciences.
What is Ligand Pharmaceuticals's ticker symbol?
The ticker symbol of Ligand Pharmaceuticals is LGND on NASDAQ.